Kairos Pharma Q2 FY26 net loss narrows to $1.39 million; revenue flat at no revenue
Reuters2026/08/12 20:18- Kairos Pharma posted a Q2 net loss of USD 1.39 million, narrowing from USD 1.42 million a year earlier.
- Operating loss improved to USD 1.42 million as total operating expenses edged down to USD 1.42 million.
- Research and development spending rose to USD 619,000, driven by a Phase 2 prostate cancer trial that began in 2024.
- General and administrative costs fell to USD 798,000; interest income slipped to USD 29,000.
- Cash and short-term investments totaled USD 2.63 million at June 30; the company flagged substantial doubt about going concern.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
